Survival Surrogates In Gastric Cancer After First- And Second-Line Chemotherapy Treatment: A Spanish Retrospective Study From One Institution

e15019 Background: Overall survival (OS) is considered the traditional endpoint for assessing the efficacy of first-line treatments in clinical trials with advanced gastric cancer. Progression free survival (PFS) has not been established as a valid surrogate endpoint for OS in the first-line setting so far. Nowadays, a range of agents like ramucirumab, taxanes or irinotecan have shown significant activity as second-line. There is scarce information about OS surrogate endpoints in the second line setting for advanced gastric cancer. Methods: We retrospectively analyzed the outcome of 47 metastatic gastric cancer patients who had received at least two consecutive chemotherapy lines of treatment at our institution from Jan 2003 to Jan 2013. We sought for overall survival surrogates by correlating first and second line overall survival (1L-OS and 2L-OS) with first and second line progression free survival (1L-PFS and 2L-PFS). We also investigated if 2L-PFS could be predicted by 1L-PFS. Spearman coefficient wa...